Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System

NCT: NCT07287176 · RECRUITING

NCT IDNCT07287176
StatusRECRUITING
Start Date2025-08-21
Completion2027-06-30

Brief Summary

The primary objective of this study is to reproduce in a multi-center study results obtained during the feasibility First-In-Human (FIH) study with Prof. Stefano Spiezia, MD (Ospedale del Mare, Naples, Italy) and to monitor additional thyroid-related symptoms and impact of patients quality of life post-ablation using a validated QoL questionnaire.

Frequently Asked Questions

What is Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System?

Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System is a clinical trial registered under NCT07287176. Current status: RECRUITING.

What is the status of NCT07287176?

The current status of NCT07287176 (Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System) is: RECRUITING.

When did Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System start?

Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System started on 2025-08-21.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑